Nxera Pharma Licenses Lucerastat for Asia Pacific
Nxera Pharma secures rights to the investigational Fabry disease therapy from Idorsia for regional development.
Updated on Oct. 28, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical companies' investments in rare diseases effectively improve patient treatment options?
Nxera Pharma has officially exercised its option to license the oral therapy lucerastat from Idorsia for Japan, South Korea, and Taiwan. The agreement includes a CHF 7 million upfront payment and positions Nxera to manage local clinical development of the treatment.
Why it matters
This deal allows Nxera Pharma to incorporate a late-stage rare disease asset into its portfolio for the Asia Pacific market. By participating in the ongoing Phase 3 global clinical program, the company aims to address a critical therapeutic gap for patients with Fabry disease.
Lucerastat is an investigational oral substrate reduction therapy currently being evaluated in a 74-patient global Phase 3 study. This clinical program compares the drug's efficacy against standard-of-care enzyme replacement therapies.
The players
Nxera Pharma
A biopharmaceutical company based in the United Kingdom focused on discovering and developing novel medicines.
Idorsia
A Swiss-based biotechnology firm specializing in the discovery and development of small molecule therapeutics.
The details
Under the terms of the deal, Nxera Pharma will take charge of clinical development within Japan and other selected Asia Pacific territories. The drug is currently moving through the FAB-KLEAR study, with findings from the global research program intended to facilitate regulatory filings starting in 2029.
Timeline
July 2023: Idorsia granted Nxera the initial option to license the therapy.
October 28, 2026: Nxera exercised the option and signed the co-development agreement.
2029: The expected timeframe for the first regulatory filing for lucerastat.
The Tech Race
The licensing agreement follows the clinical milestones and development requirements established by the ongoing FAB-KLEAR Phase 3 clinical trial. This move signals a broader transition toward specialized oral therapies that aim to replace legacy intravenous enzyme replacement regimens.
For patients with Fabry disease, this development signals a potential shift toward oral substrate reduction therapies that could simplify long-term treatment. Future commercialization in Japan and Asia Pacific may eventually provide an alternative to traditional, invasive enzyme replacement options.
The takeaway
This partnership highlights the strategic push by regional pharmaceutical firms to secure late-stage assets in the rare disease space. Expanding clinical development into Asia Pacific represents a significant step in the global effort to bring substrate reduction therapies to more patients.
Further reading
Learn more about evolving Biotech trends and clinical trial developments.
Live Poll
Do you trust that pharmaceutical companies' investments in rare diseases effectively improve patient treatment options?
